Drug
Kx2 391
Kx2 391: highest development phase Phase 2, developed by Athenex, United Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Athenex, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| KX2-391 NCT01074138 | Phase 2 | Bone-Metastatic, Castration-Resistant Prostate Cancer |
| KX2-391 NCT01397799 | Phase 1 | Acute Myelogenous Leukemia |
| KX2-391 NCT00658970 | Phase 1 | Solid Tumors |
| KX2-391 Ointment NCT02337205 | Phase 1 | Actinic Keratosis |
Latest
No recent events.
Follow Kx2 391 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.